2022
Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry
Meagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Roussel E, Pavan N, Antonelli A, Zhang S, Ghali F, Patel D, Javier-Desloges J, Bradshaw A, Rubio J, Guruli G, Tracey A, Campi R, Albersen M, Furlan M, McKay RR, Derweesh IH. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. Clinical Genitourinary Cancer 2022, 20: 326-333. PMID: 35585014, DOI: 10.1016/j.clgc.2022.03.013.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaCancer-specific mortalityKaplan-Meier analysisHigh-risk groupImpact of metastasectomyRenal cell carcinomaCell carcinomaMultimodal management strategyPotential prognostic variablesHigh-risk patientsMulticenter retrospective analysisCox regression analysisIntermediate-risk subgroupsMedian OSMRCC patientsCause mortalitySurgical metastasectomyOverall survivalPrimary outcomeSecondary outcomesSpecific survivalCox regressionCancer-SpecificTreatment paradigmMetastasectomy
2020
Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma
Roussel E, Campi R, Larcher A, Verbiest A, Antonelli A, Palumbo C, Derweesh I, Ghali F, Bradshaw A, Meagher M, Heck M, Amiel T, Kriegmair M, Rubio J, Musquera M, D’Anna M, Autorino R, Guruli G, Veccia A, Linares-Espinos E, Van Bruwaene S, Hevia V, Porpiglia F, Checcucci E, Minervini A, Mari A, Pavan N, Claps F, Marchioni M, Capitanio U, Beuselinck B, Mir M, Albersen M, Group O. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. European Urology Oncology 2020, 3: 523-529. PMID: 32414697, DOI: 10.1016/j.euo.2020.04.006.Peer-Reviewed Original ResearchConceptsCytoreductive nephrectomyPostoperative complicationsMultivariable analysisMRCC patientsIntraoperative complicationsBlood lossSignificant predictorsComplex surgeryMetastatic renal cell carcinoma patientsHigher intraoperative blood lossHigh-grade postoperative complicationsMetastatic renal cell carcinomaRenal cell carcinoma patientsCase loadHigh-grade morbidityMultiple postoperative complicationsIntraoperative blood lossMetastatic renal cancerCell carcinoma patientsPrimary kidney tumorsRenal cell carcinomaLogistic regression analysisTherapy eraPerioperative complicationsPostoperative morbidity
2016
Does Travel Time to a Radiation Facility Impact Patient Decision‐Making Regarding Treatment for Prostate Cancer? A Study of the New Hampshire State Cancer Registry
Ghali F, Celaya M, Laviolette M, Ingimarsson J, Carlos H, Rees J, Hyams E. Does Travel Time to a Radiation Facility Impact Patient Decision‐Making Regarding Treatment for Prostate Cancer? A Study of the New Hampshire State Cancer Registry. The Journal Of Rural Health 2016, 34: s84-s90. PMID: 27862285, DOI: 10.1111/jrh.12224.Peer-Reviewed Original ResearchConceptsNew Hampshire State Cancer RegistrySeason of diagnosisState Cancer RegistryNearest radiation facilityCancer RegistryProstate cancerTreatment decisionsRisk categoriesExternal beam radiation therapyD'Amico risk categoryLocalized prostate cancerYears of treatmentMultivariable regression analysisBeam radiation therapyHigh-risk categoryWinter diagnosisMultivariable analysisRadiation therapyNew diagnosisSignificant interactionMarried statusRural residenceOlder agePatientsUrban residence